17129
document
Weight and leptin changes among risperidone-treated youths with autism : 6-month prospective data . OBJECTIVE The authors examined the developmental impact and temporal characteristics of risperidone-associated weight change . METHOD Weight change was measured for 63 children and adolescents with autism treated with risperidone for 6 months . Change in serum leptin levels after 2 months was examined as a predictor of final weight gain in mixed regression models that controlled for site , gender , age , and risperidone dose . RESULTS Age- and gender-standardized weight increased after 6 months of treatment ( gross : mean=5.6 kg [ SD=3.9 ] ; standardized : mean=0.6 z [ SD=0.5 ] ) and was positively correlated with weight gained after 1 month . Change in leptin levels after 2 months of treatment ( mean=-0.3 ng/ml , SD=6.2 ) ( N=48 ) did not predict final weight gain . CONCLUSIONS Chronic risperidone exposure in children with autism causes weight gain in excess of developmentally expected norms that follows a curvilinear trajectory and decelerates over time . Serum leptin change does not reliably predict risperidone-associated weight gain .
17130
Intervention_Pharmacological
risperidone-treated
17131
Intervention_Pharmacological
risperidone-associated
17132
Intervention_Pharmacological
risperidone
17133
Intervention_Pharmacological
risperidone
17134
Intervention_Pharmacological
risperidone
17135
Outcome_Physical
Weight
17136
Outcome_Physical
leptin changes
17137
Outcome_Physical
weight change
17138
Outcome_Physical
Weight change
17139
Outcome_Physical
Change in serum leptin levels
17140
Outcome_Physical
final weight gain
17141
Outcome_Physical
weight increased
17142
Outcome_Physical
weight gained
17143
Outcome_Physical
Change in leptin levels
17144
Outcome_Physical
final weight gain
17145
Outcome_Physical
weight gain
17146
Outcome_Physical
Serum leptin change
17147
Outcome_Physical
weight gain